Announcement • May 15
Zura Bio Limited Appoints Muzammil Mustufa as Chief Business Officer Zura Bio Limited announced the appointment of Muzammil Mustufa as Chief Business Officer (CBO). Mr. Mustufa will oversee corporate strategy, business development, commercial planning, and investor relations efforts. Mr. Mustufa brings 20 years of diversified pharmaceutical and biotechnology experience to Zura, with extensive experience in immunology, rare disease, and other therapeutic areas. Most recently, he served as Vice President of Corporate Strategy at Amicus Therapeutics, where he played an integral part in the global launch and commercialization strategies of two innovative medicines in orphan diseases. He subsequently led integration planning for Amicus in connection with BioMarin Pharmaceutical Inc.'s $4.8 billion acquisition of the company. Earlier in his career, Mr. Mustufa held roles at GSK plc, The Frankel Group, and The D.E. Shaw Group. Announcement • May 04
Zura Bio Limited, Annual General Meeting, Jun 17, 2026 Zura Bio Limited, Annual General Meeting, Jun 17, 2026. Announcement • Mar 06
Zura Bio Limited to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual Il-17A and Baff Inhibition in Systemic Sclerosis At 9Th Systemic Sclerosis World Congress Zura Bio Limited announced that the design of its ongoing Phase 2 TibuSURE clinical trial evaluating tibulizumab (ZB-106) in systemic sclerosis (SSc) has been accepted for poster presentation at the Systemic Sclerosis World Congress, taking place March 5–7, 2026 in Athens, Greece. The poster, titled “TibuSURE: A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis” (Abstract ID 184; Poster P.267), outlines the rationale and design of the global Phase 2 study. No clinical efficacy or safety data will be presented. Diffuse cutaneous systemic sclerosis (“dcSSc”) is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including the lungs. Treatment options remain limited, highlighting the need for therapeutic approaches that address multiple drivers of disease biology. TibuSURE is the first clinical trial designed to evaluate the dual inhibition of interleukin-17A (“IL-17A”) and B-cell activating factor (“BAFF”) in dcSSc. Tibulizumab is an investigational bispecific antibody engineered to simultaneously neutralize IL-17A and BAFF, two cytokines implicated in inflammation, autoimmunity and fibrotic progression in SSc. By targeting complementary immune pathways, tibulizumab represents a differentiated investigational strategy intended to modulate both inflammatory and fibrotic disease processes. The ongoing global Phase 2 study is expected to enroll approximately 80 adults who will be randomized 1:1 to receive tibulizumab or placebo every four weeks for 24 weeks, followed by a 28-week open-label extension. The primary endpoint is change from baseline in modified Rodnan Skin Score at Week 24. Topline results are currently anticipated in the first half of 2027. 
